Drug Metabolism and disPosition

Article	Citations
Editorial Board	113
Editorial Board	102
Table of Contents	98
The role of cytochrome P450 and gut microbiome in drug metabolism: Insights into Parkinson disease treatment	61
Quantitative Proteomics for Translational Pharmacology and Precision Medicine: State of The Art and Future Outlook	60
Evaluation of Drug-Drug Interactions via Inhibition of Hydrolases by Orlistat, an Anti-Obesity Drug	55
CYP3A4 and CYP3A5 Expression is Regulated by C YP3A4*1G in CRISPR/Cas9-Edited HepG2 Cells	53
Quantitative Analysis of mRNA and Protein Expression Levels of Aldo-Keto Reductase and Short-Chain Dehydrogenase/Reductase Isoforms in the Human Intestine	53
Metabolism and Disposition of [14C]Pevonedistat, a First-in-Class NEDD8-Activating Enzyme Inhibitor, after Intravenous Infusion to Patients with Advanced Solid Tumors	49
A Comprehensive Evaluation of the Effects of RNA-Editing Proteins ADAR and ADARB1 on the Expression of the Drug-Metabolizing Enzymes in HepaRG Cells	47
Application of preclinical absorption, distribution, metabolism, elimination in vitro techniques for the characterization and compound library optimization of novel antibiotic gallium salophen	43
Epigenetic Activation of Cytochrome P450 1A2 Sensitizes Hepatocellular Carcinoma Cells to Sorafenib	37
Inhibitory effects of Δ8-tetrahydrocannabinol on major hepatic cytochrome P450 enzymes and implications for drug disposition	35
Advances in organ-on-chip for drug transporters study: Key insights and hurdles	34
From Steroid and Drug Metabolism to Glycobiology, Using Sulfotransferase Structures to Understand and Tailor Function	34
Hepatic uptake of estradiol-3-glucuronide and estradiol-3-sulfate-17β-glucuronide by human organic anion transporting polypeptides 1B1, 1B3, and 2B1	34
Synergistic Hepatotoxicity of Azithromycin and Acetaminophen Involves LXRα-mediated Metabolic Dysregulation and Endoplasmic Reticulum Stress	32
Predictive Performance of Physiologically Based Pharmacokinetic Modelling of Beta-Lactam Antibiotic Concentrations in Adipose, Bone, and Muscle Tissues	31
Dissecting Parameters Contributing to the Underprediction of Aldehyde Oxidase-Mediated Metabolic Clearance of Drugs	31
Pharmacokinetic insights of onradivir in influenza treatment to inform pediatric dosing selection in clinical trial	31
Early Prediction and Impact Assessment of CYP3A4-Related Drug-Drug Interactions for Small-Molecule Anticancer Drugs Using Human-CYP3A4-Transgenic Mouse Models	27
Combining the novel all-human co-cultured hepatocytes system with physiologically based pharmacokinetic modeling to assess the translatability of cytochrome P450 and uridine 5′-diphospho-glucuronosylt	27
Cytochrome P450 Enzymes as Drug Targets in Human Disease	26
Ketone reduction drives major circulating metabolites of GDC-8264 in humans	26
Gut microbial resistance and metabolism of selective serotonin reuptake inhibitors drive multidrug resistance and contribute to antidepressant tachyphylaxis	25

Interaction and Transport of Benzalkonium Chlorides by the Organic Cation and Multidrug and Toxin Extrusion Transporters	25
Population pharmacokinetic analysis of onradivir to support dosing recommendations in elderly adults with influenza	25
A combination of dietary cholesterol and cholic acid induces hepatic expression of proinflammatory genes accompanied by changes in sterol metabolism and redox status	24
Editorial Board	23
Contents	23
Editorial Board	23
Recent Advances in Mass Spectrometry-Based Spatially Resolved Molecular Imaging of Drug Disposition and Metabolomics	22
CYP7A1 Gene Induction via SHP-Dependent or Independent Mechanisms can Increase the Risk of Drug-Induced Liver Injury Independently or in Synergy with BSEP Inhibition	21
In Vitro Assay for Quantitative Prediction of Human Intestinal Drug Absorption with Cryopreserved Human Intestinal Mucosal Epithelium-Derived Intestinal Stem Cells and 96-Well Vitrigel Inserts	21
Investigations into the Concentrations and Metabolite Profiles of Doping Agents and Antidepressants in Human Seminal Fluid Using Liquid Chromatography–Mass Spectrometry	21
Humanized-liver TK-NOG mice lacking plasma carboxylesterase 1c improve the prediction of human carboxylesterase 1-mediated drug metabolism	21
Mass Balance of the Indoleamine 2,3-Dioxygenase Inhibitor Navoximod (GDC-0919) in Rats and Dogs: Unexpected Cyanide Release from Imidazo[5,1-a]isoindole and Species Differences in Glucuronidation	21
Characterization of organic anion transporting polypeptide (OATP)1B1 and OATP1B3 humanized rat as a translational model to study the pharmacokinetics of OATP1B substrate drugs	21
Impact of the loss of slc43a3 on 6-mercaptopurine absorption and tissue distribution in mice	20
Methotrexate gene polymorphisms link to toxicity but not pharmacokinetics in Chinese adults and adolescents with acute lymphoblastic leukemia	20
Quantitative Consideration of Clinical Increases in Serum Creatinine Caused by Renal Transporter Inhibition	20
SND1 Regulates Organic Anion Transporter 2 Protein Expression and Sensitivity of Hepatocellular Carcinoma Cells to 5-Fluorouracil	20
The Unique Human N10-Glucuronidated Metabolite Formation from Olanzapine in Chimeric NOG-TKm30 Mice with Humanized Livers	20
Corrigendum to “Human cytochrome P4502C8 metabolizes repaglinide to 4′-hydroxyrepaglinide, not 3′-hydroxyrepaglinide” [Drug Metabolism and Disposition 53 (2025) 100177]	19
Quantitative distribution of theobromine in mouse brain regions and its mitigation of nicotine withdrawal–induced anxiety and depression through neuroinflammation suppression	19
Quantitative Prediction of Drug-Drug Interactions Caused by CYP3A Induction Using Endogenous Biomarker 4β-Hydroxycholesterol	19
MegaTrans—machine learning models for drug transporters corresponding to the FDA guidance	19
Special Section on Drug Metabolism and Precision Medicine—Editorial	18
Editorial Board	18
Intestine versus liver? Uncovering the hidden major metabolic organs of silybin in rats	18
Examining Physiologically Based Pharmacokinetic Model Assumptions for Cross-Tissue Similarity of Activity per Unit of Enzyme: The Case Example of Uridine 5′-Diphosphate Glucuronosyltransferase	18
Human Cytochrome P450 27A1 - a variety of reactions, applications, and potentials for drug targeting	18
On the interface of fatty acid metabolism: A crosstalk between fatty acid ω-hydroxylase CYP4F11 and fatty acid desaturase 2 in non–small cell lung cancer	18
Drug-drug interactions induced by immunosuppressants through inhibition of human carboxylesterases	18
Exogenous Pregnane X Receptor Does Not Undergo Liquid–Liquid Phase Separation in Nucleus under Cell-Based In Vitro Conditions	17
Multispecies minimal physiologically based pharmacokinetic-pharmacodynamic model of antisense oligonucleotides for central nervous system disorders	17
The Current Status and Use of Microphysiological Systems by the Pharmaceutical Industry: The International Consortium for Innovation and Quality Microphysiological Systems Affiliate Survey and Comment	17
Clearance prediction with three novel plated human hepatocyte models compared to conventional suspension assays: Assessment with 50 compounds and multiple donors	17
Correlations of Long Noncoding RNA HNF4A-AS1 Alternative Transcripts with Liver Diseases and Drug Metabolism	17
Antibiotics-Induced Disruption of Gut Microbiota Increases Systemic Exposure of Clopidogrel Active Metabolite in Type 2 Diabetic Rats	17
Rat PermQ: A permeability- and perfusion-based physiologically based pharmacokinetic model for improved prediction of drug concentration-time profiles in rat	16
Finding the Dispersion Number (D) of the Dispersion Model from Perfused Rat and Human Liver Studies	16
Improved clearance predictions for aldehyde oxidase substrates using a novel triculture human hepatocyte model	16
The Metabolism and Disposition of Brepocitinib in Humans and Characterization of the Formation Mechanism of an Aminopyridine Metabolite	16
Characterization of Xenobiotic and Steroid Disposition Potential of Human Placental Tissue and Cell Lines (BeWo, JEG-3, JAR, and HTR-8/SVneo) by Quantitative Proteomics	16
Preclinical translational physiologically based pharmacokinetic modeling for predicting human pharmacokinetics of proteolysis targeting chimeras: Case studies of vepdegestrant (ARV-471) and bavdegalut	16
The Role of Coproporphyrins As Endogenous Biomarkers for Organic Anion Transporting Polypeptide 1B Inhibition–Progress from 2016 to 2023	16
Insights into the human pharmacokinetics and metabolism of branaplam, a splicing modulator of a survival motor neuron-2 and huntingtin pre-mRNAs, in infants and adults	16
Absorption, Distribution, Metabolism, and Excretion of Icenticaftor (QBW251) in Healthy Male Volunteers at Steady State and In Vitro Phenotyping of Major Metabolites	15
Table of Contents	15
Evaluation of small interfering RNA–dependent knockdowns of drug-metabolizing enzymes in multiwell array culture of primary human hepatocyte spheroids for estimation of fraction metabolized	15
Mechanism of hydroxamic acid group metabolism to carboxylic acid: Oxidation versus hydrolysis	15
The regulation of organic anion transporting polypeptide 1B1 by nonreceptor tyrosine kinase YES1	15
Differential Tissue Abundance of Membrane-Bound Drug Metabolizing Enzymes and Transporter Proteins by Global Proteomics	15
The application of mechanistic absorption, distribution, metabolism and excretion studies and physiologically-based pharmacokinetic modeling in the discovery of the next-generation oral selective estr	14

In Vitro CYP450 Enzyme Downregulation by GLP-1/Glucagon Coagonist Does Not Translate to Observed Drug-Drug Interactions in the Clinic	14
Mycobacterium abscessus CYP123 is a steroid hydroxylase with an implication in host infection	14
Insights into the renal protective effects of 7-phenylheptanoic acid in chronic kidney disease mice: Modulation of indoxyl sulfate production and gut microbiome homeostasis	14
Phenobarbital in Nuclear Receptor Activation: An Update	14
Profiling RNA metabolism to understand tissue and subcellular clearance of therapeutic RNA	14
Human absorption, distribution, metabolism, excretion, and reaction phenotyping of ervogastat (PF-06865571), a diacylglycerol O-acyltransferase 2 inhibitor	14
Multidisciplinary Insights into the Structure–Function Relationship of the CYP2B6 Active Site	14
Use of a Double-Transfected System to Predict hOCT2/hMATE1-Mediated Renal Drug–Drug Interactions	14
Mesenchymal Stem Cell Fates in Murine Acute Liver Injury and Chronic Liver Fibrosis Induced by Carbon Tetrachloride	14
Assessing granisetron as a specific CYP1A1 substrate in primary human hepatocytes: A comprehensive evaluation for drug development studies	14
Characterization of human intestinal organoid-derived monolayers under air-liquid interface culture for pharmacokinetics evaluation	14
Editorial Board	13
Involvement of Proton-Coupled SLC49A4-Mediated Transport in the Export of Lysosomally Trapped Pyrilamine	13
Development and Validation of a Proteomic Correlation Profiling Technique to Detect and Identify Enzymes Involved in Metabolism of Drugs of Concern	13
Pharmacogenetic Influence on Stereoselective Steady-State Disposition of Bupropion	13
Corrigendum to “Upregulation of hepatic flavin-containing monooxygenase 3 by increased corticosterone via glucocorticoid receptor contributes to gestational diabetes mellitus” [Drug Metabolism and Dis	13
Unraveling enantioselective metabolism: Human cytochrome P450s in arachidonic acid biotransformation	13
Application of Empirical Scalars To Enable Early Prediction of Human Hepatic Clearance Using In Vitro-In Vivo Extrapolation in Drug Discovery: An Evaluation of 173 Drugs	13
Editorial Board	13
Table of Contents	13
Efflux transporters in drug disposition during pregnancy	12
Prediction of CYP3A-mediated drug–drug interactions using endogenous biomarkers 6β-hydroxycortisol and cortisol	12
Characterization of hydrolase activity in ocular tissues of humans and preclinical species	12
Decreased expression of P-glycoprotein in the placenta of women with autoimmune disease	12
Heterotropic allosteric modulation of CYP3A4 in vitro by progesterone: Evidence for improvement in prediction of time-dependent inhibition for macrolides	12
Arsenite-Induced Drug–Drug Interactions in Rats	12
Investigating the Correlation between Genotypes and Hepatic Protein Expression of CYP2C9, CYP2C19, CYP2D6, and CYP3A5 Using Postmortem Tissue from a Danish Population	12
Fluorescence-Based High-Throughput Assays for Investigating Cytochrome P450 Enzyme-Mediated Drug–Drug Interactions	12
Central Mechanisms of Acetaminophen Hepatotoxicity: Mitochondrial Dysfunction by Protein Adducts and Oxidant Stress	12
Development of a generic physiologically based pharmacokinetic model to predict clinical pharmacokinetics and assess drug–drug interaction risks for valine–citrulline–monomethyl auristatin E–based ant	12
Nonclinical Pharmacokinetics Study of OLX702A-075-16, N-Acetylgalactosamine Conjugated Asymmetric Small Interfering RNA (GalNAc-asiRNA)	12
A Phase I Study To Determine the Absolute Bioavailability and Absorption, Distribution, Metabolism, and Excretion of Capivasertib in Healthy Male Participants	12
Virtual Special Section: Sex and Hormonal Influences on Drug Metabolism and Disposition, and Related Studies	12
Regulation of Nuclear Receptors PXR and CAR by Small Molecules and Signal Crosstalk: Roles in Drug Metabolism and Beyond	12
Assessing Trends in Cytokine–CYP Drug Interactions and Relevance to Drug Dosing	11
After 50 Years of Hepatic Clearance Models, Where Should We Go from Here? Improvements and Implications for Physiologically Based Pharmacokinetic Modeling	11
Hydroxychloroquine is Metabolized by Cytochrome P450 2D6, 3A4, and 2C8, and Inhibits Cytochrome P450 2D6, while its Metabolites also Inhibit Cytochrome P450 3A in vitro	11
Unveiling hepatic Krüppel-like factor 15 as the key regulator of cyclosporine A metabolism and adverse effects	11
New strategy to quantify hepatic cytochrome P450 3A activity with deoxyschizandrin as an in vivo probe: A V approach	11
CYP3A5 polymorphism affects the disposition of tacrolimus and its metabolite in systemic circulation and peripheral tissues of mice introduced with the CYP3A5 gene	11
Evaluation of reversible cytochrome P450 inhibition by Withania somnifera leaf and root extracts	11
Evaluation of various experimental conditions and mechanistic static versus dynamic models to predict time-dependent CYP3A4/5 inhibition potential of drugs	11
Organic cation transporter 1 and cytochrome P450s play crucial roles in coptisine- and worenine-induced hepatotoxicity	11
Adipocyte-Derived PXR Signaling Is Dispensable for Diet-Induced Obesity and Metabolic Disorders in Mice	11
Prediction of pharmacokinetics and CNS effects of fentanyl and alfentanil in mice, rats and humans using cross-species PBPK-PD model and in vitro PK/PD parameters	11
Evaluation of the Selectivity of Several Organic Anion Transporting Polypeptide 1B Biomarkers Using Relative Activity Factor Method	11
The Absolute Bioavailability and Absorption, Metabolism, and Excretion of Ipatasertib, a Potent and Highly Selective Protein Kinase B (Akt) Inhibitor	11
Clinical Relevance of the Constitutive Androstane Receptor	11
Preclinical Metabolism and Disposition of TP0473292, a Novel Oral Prodrug of the Potent Metabotropic Glutamate 2/3 Receptor Antagonist TP0178894 for the Treatment of Depression	11
Novel Approaches to Characterize Individual Drug Metabolism and Advance Precision Medicine	11
Metabolism and excretion pathways of CD388, a novel drug-fragment crystallizable conjugate for prevention of seasonal or pandemic influenza	11
Utilization of a human Liver Tissue Chip for drug-metabolizing enzyme induction studies of perpetrator and victim drugs	11
CYP1A2 expression and activity in a large panel of human nonneoplastic surgical liver samples: Influence of genetics, lifestyle, and other factors	11
Mechanistic Study on the Species Differences in Excretion Pathway of HR011303 in Humans and Rats	10
Efficient protein quantification in drug metabolism and pharmacokinetics with an accelerated proteomic workflow	10
Editorial Board	10
Characterization of the specific proteins to which HH-A, a drug that alleviates ischemic brain injury, binds in rat plasma	10
Impact of Inflammation and Infection on the Expression of Amino Acid Transporters in the Placenta: A Minireview	10
Newly Identified Tree Shrew Cytochrome P450 2A13 is Expressed in Liver and Lung and Encodes a Functional Drug-Metabolizing Enzyme Similar to Dog Cytochrome P450 2A13 and Pig Cytochrome P450 2A19	10
Kirchhoff’s Laws and Hepatic Clearance, Well-Stirred Model – Is There Common Ground?	10
Physiologically Based Pharmacokinetic Modeling To Predict Drug-Biologic Interactions with Cytokine Modulators: Are These Relevant and Is Interleukin-6 Enough?	10
Erratum to “After 50 Years of Hepatic Clearance Models, Where Should We Go from Here? Improvements and Implications for Physiologically Based Pharmacokinetic Modeling”	10
Covalent Binding Mechanism of Furmonertinib and Osimertinib With Human Serum Albumin	10
The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Ritlecitinib, a Janus Kinase 3 and Tyrosine-Protein Kinase Family Inhibitor, in Humans	10
Physiologically-Based Pharmacokinetics of Dexamethasone in Rats Featuring Nonlinear Tissue Binding	10
CYP2B6 downregulation by cell-penetrating dominant-negative activating transcription factor 5 peptide in glioblastoma cells	10
Quetiapine competitively inhibits aldehyde oxidase-mediated reduction	10
Effects of Strong Inhibition of Cytochrome P450 3A and UDP glucuronosyltransferase 1A9 and Strong Induction of Cytochrome P450 3A on the Pharmacokinetics, Safety, and Tolerability of Soticlestat: Two	10
Table of Contents	10
The African Liver Tissue Biorepository Consortium: Capacitating Population-Appropriate Drug Metabolism, Pharmacokinetics, and Pharmacogenetics Research in Drug Discovery and Development	10
Enzyme-substrate-inactivator complex formation can impact time-dependent inhibition kinetics	10
A Cross Company Perspective on the Assessment of Therapeutic Protein Biotransformation	9
In Vitro Reaction Phenotyping and Projection of Drug Interactions Mediated by Cytochrome P450 Enzymes for Central Nervous System Drugs as Victims: Implications for Safety in Vulnerable Populations	9
Table of Contents	9
Mass spectrometry footprinting reveals microsomal CYP2A6 structural changes induced by interaction with its reductase flavin mononucleotide domain	9
Significance of gut breast cancer resistance protein versus organic anion transporting polypeptide 2B1 inhibition on rosuvastatin clinical drug-drug interactions	9
1β-Hydroxydeoxycholic acid as an endogenous biomarker in human plasma for assessment of drug-drug interaction with moderate CYP3A inhibitor	9
Novel O-methylpyrimidine prodrugs of phenolic compounds bioactivated by aldehyde oxidase: Enhancing metabolic stability against first-pass conjugative metabolism in the intestine	9
Evaluation of the disconnect between hepatocyte and microsomal intrinsic clearance at intracellular and extracellular pH	9
Characterization of Pharmacokinetics, Biotransformation and Elimination of Pomotrelvir Orally Administered in Healthy Male Adults Using Two [14C]-Labeled Microtracers with Separate Labeling Positions	9

Special Section on Pharmacokinetics and ADME of Biological Therapeutics–Editorial	9
Quantitative Evaluation of the Contribution of Each Aldo-Keto Reductase and Short-Chain Dehydrogenase/Reductase Isoform to Reduction Reactions of Compounds Containing a Ketone Group in the Human Liver	9
Table of Contents	9
Table of Contents	9
Combined Oral Contraceptives As Victims of Drug Interactions	9
Advancing precision treatment in preterm infants: Population pharmacokinetics of caffeine for apnea of prematurity	9
Predicting Clearance with Simple and Permeability-Limited Physiologically Based Pharmacokinetic Frameworks: Comparison of Well-Stirred, Dispersion, and Parallel-Tube Liver Models	9
Prediction of human hepatic clearance with HepaSH monolayers for low-turnover compounds	9
Searching for Constitutive Androstane Receptor Modulators	9
Real-world application of physiologically based pharmacokinetic models in drug discovery	8
Table of Contents	8
Erratum to “A semimechanistic PK/PD model–informed Taxus tablets’ development: Accelerating early clinical translation of a taxane-based antitumor agent” [Drug Metabolism and Disposition 54 (2026) 100	8
Ontogeny of Hepatic Organic Cation Transporter-1 in Rat and Human	8
The rs35217482 (T755I) Single-Nucleotide Polymorphism in Aldehyde Oxidase-1 Attenuates Protein Dimer Formation and Reduces the Rates of Phthalazine Metabolism	8
Challenges and Opportunities for In Vitro–In Vivo Extrapolation of Aldehyde Oxidase-Mediated Clearance: Toward a Roadmap for Quantitative Translation	8
Development of human embryonic stem cell-derived cardiomyocytes and application of fluorescence probe substrate for characterization of cytochrome P450 enzyme 2J2	8
Correction to “Dissecting Parameters Contributing to the Underprediction of Aldehyde Oxidase-Mediated Metabolic Clearance of Drugs”	8
In vitro metabolism studies of 5 acrylamide covalent drugs: Comparison with metabolism and disposition in human	8
Curcumin enhances the oral bioavailability of testosterone by inhibiting its intestinal metabolism	8
Xenografted Tumors Share Comparable Fraction Unbound and Can Be Surrogated by Mouse Lung Tissue	8
Progress in the Quantitative Assessment of Transporter-Mediated Drug–Drug Interactions Using Endogenous Substrates in Clinical Studies	8
There and Back Again: A Perspective on 20 Years of CYP4Z1	8
Manuscript DMD-D-25-00346 The impact of glycocalyx on partitioning and distribution of basic drugs	8
Cytochrome P450 and Other Drug-Metabolizing Enzymes As Therapeutic Targets	8
Structure and properties of an oxidative metabolite of 2-methoxy-N-[3-[4-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]anilino]-6-quinazolinyl]prop-2-enyl]acetamide generated by aldehyde oxidase	8
The In Vivo Pharmacokinetics of Block Copolymers Containing Polyethylene Glycol Used in Nanocarrier Drug Delivery Systems	8
Characterization of intestinal transporters in human ileal spheroid–derived differentiated cells for the prediction of intestinal drug absorption	8
Transporter-Enzyme Interplay in the Pharmacokinetics of PF-06835919, a First-In-Class Ketohexokinase Inhibitor for Metabolic Disorders and Nonalcoholic Fatty Liver Disease	8
Pregnane X receptor, constitutive androstane receptor, or peroxisome proliferator–activated receptor α activation does not affect yes-associated protein phase separation under physiological and hypero	8
The Simultaneous Inhibition of Solute Carrier Family 6 Member 19 and Breast Cancer Resistance Protein Transporters Leads to an Increase of Indoxyl Sulfate (a Uremic Toxin) in Plasma and Kidney	8
Bridging in vitro and clinical data: Experimental insights into the IC50 variability of dolutegravir as an organic cation transporter 2 inhibitor	8
Epigenetic Mechanisms Contribute to Intraindividual Variations of Drug Metabolism Mediated by Cytochrome P450 Enzymes	8
Inactivation of Human Aldehyde Oxidase by Small Sulfhydryl-Containing Reducing Agents	8
Prediction of Drug–Drug Interactions with Ensartinib as a Time-Dependent CYP3A Inhibitor Using Physiologically Based Pharmacokinetic Model	7
CYP P450 and non-CYP P450 Drug Metabolizing Enzyme Families Exhibit Differential Sensitivities towards Proinflammatory Cytokine Modulation	7
Ontogeny of Scaling Factors for Pediatric Physiologically Based Pharmacokinetic Modeling and Simulation: Cytosolic Protein Per Gram of Liver	7
In Vitro Evaluation of the Reductase Activities of Human AKR1C3 Allelic Variants	7
Sex-dependent alterations in cardiac cytochrome P450-mediated arachidonic acid metabolism in pressure overload–induced cardiac hypertrophy in rats	7
Impact of genetic polymorphisms and drug-drug interactions mediated by carboxylesterase 1 on remimazolam deactivation	7
Mass Balance, Metabolic Pathways, Absolute Bioavailability, and Pharmacokinetics of Giredestrant in Healthy Subjects	7
Heterodimerization of Human UDP-Glucuronosyltransferase 1A9 and UDP-Glucuronosyltransferase 2B7 Alters Their Glucuronidation Activities	7
The COVID-19 Oral Drug Molnupiravir Is a CES2 Substrate: Potential Drug-Drug Interactions and Impact of CES2 Genetic Polymorphism In Vitro	7
Early-stage prediction of human intestinal metabolism from in vitro liver microsomal clearance	7
The Important Role of Transporter Structures in Drug Disposition, Efficacy, and Toxicity	7
The regulatory potential of cytochrome P450–Adrenodoxin interactions: insights toward understanding redox partner regulation in drug metabolizing enzymes	7
The Role of Mechanistic Biomarkers in Understanding Acetaminophen Hepatotoxicity in Humans	7
Exploring the main source of coproporphyrins: Observations on transport in red blood cells	7
Editorial Board	7
Table of Contents	7
Dimethandrolone, a Potential Male Contraceptive Pill, is Primarily Metabolized by the Highly Polymorphic UDP-Glucuronosyltransferase 2B17 Enzyme in Human Intestine and Liver	7
Perspective of the Induction of Liver Microsomal Cytochrome P450s by Chemical Compounds	7
Stable and functional human intestinal epithelium derived from induced pluripotent stem cells	7
Impact of Heterotropic Allosteric Modulation on the Time-Dependent Inhibition of Cytochrome P450 3A4	7
Prediction of Human Pharmacokinetics of Phosphorodiamidate Morpholino Oligonucleotides in Duchenne Muscular Dystrophy Patients Using Viltolarsen	7
HNF4A-AS1 promotes hepatic steatosis in metabolic dysfunction–associated steatotic liver disease by driving HNF4A degradation	7
Pharmacokinetic Modeling of Warfarin І – Model-Based Analysis of Warfarin Enantiomers with a Target Mediated Drug Disposition Model Reveals CYP2C9 Genotype-Dependent Drug-Drug Interactions of S-Warfar	7
Tissue-, Region-, and Gene-Specific Induction of Microsomal Epoxide Hydrolase Expression and Activity in the Mouse Intestine by Arsenic in Drinking Water	7
Identification and Validation of Active Ingredient in Cerebrotein Hydrolysate-I Based on Pharmacokinetic and Pharmacodynamic Studies	7
The Role of Intramolecular Reactions and Chemical Degradation in the Apparent Biotransformation Pathways of a Series of SYK Inhibitors	7
COVID-19 Vaccines and the Virus: Impact on Drug Metabolism and Pharmacokinetics	7
A Physiological-Based Pharmacokinetic Model Embedded with a Target-Mediated Drug Disposition Mechanism Can Characterize Single-Dose Warfarin Pharmacokinetic Profiles in Subjects with Various CYP2C9 Ge	6
The Nonclinical Disposition and Pharmacokinetic/Pharmacodynamic Properties of N-Acetylgalactosamine–Conjugated Small Interfering RNA Are Highly Predictable and Build Confidence in Translation to Human	6
Table of Contents	6
Activation/Inactivation of Anticancer Drugs by CYP3A4: Influencing Factors for Personalized Cancer Therapy	6
Molnupiravir is not a selective CES2 probe substrate: in vitro evidence for CES1 involvement	6
Impact of variation in CYP3A and CYP2C8 on tucatinib metabolic clearance in human liver microsomes	6
Dual effects of a new CYP2E1 inhibitor on gout: Anti-inflammatory actions and lowered uric acid levels	6
Keratinocyte transport of notoginsenoside R1 via ABCG2: A novel mechanism for RNA N-methyladenosine modification in UVB induced skin sunburn injury	6
Process and System Clearances in Pharmacokinetic Models: Our Basic Clearance Concepts Are Correct	6
An Integrated Hepatocyte Stability Assay for Simultaneous Metabolic Stability Assessment and Metabolite Profiling	6
Inhibitory effects of Δ8-tetrahydrocannabinol on nicotine metabolism and implications as a smoking cessation agent	6
Absolute membrane protein abundance of P-glycoprotein, breast cancer resistance protein, and multidrug resistance proteins in term human placenta tissue and commonly used cell systems: Application in	6
Application of small interfering RNA technology in cytochrome P450 gene modulation	6
Table of Contents	6
Comparative evaluation of ultrafiltration and EMSA formats for siRNA plasma protein binding: Methodological determinants and artifacts	6
Evidence for endogenous amine conjugation and cytotoxicity arising from metabolic activation of trazodone	6
Individualized Pharmacotherapy Utilizing Genetic Biomarkers and Novel In Vitro Systems As Predictive Tools for Optimal Drug Development and Treatment	6
Design, expression, purification, and application of novel recombinant miR-491 molecules to define the biogenesis and function of miR-491-3p versus -5p in posttranscriptional regulation of UDP-glucuro	6
A drug-to-metabolite ratio-based quantitative analytical approach for evaluation of combination therapy through impact assessment of brigatinib on the pharmacokinetics of tazemetostat and its primary	6
Lirafugratinib attenuates ABCG2-dependent drug efflux and restores chemosensitivity in multidrug-resistant nonsmall cell lung cancer cells	6
Systemic Exposure, Metabolism, and Elimination of [14C]-Labeled Amino Lipid, Lipid 5, after a Single Administration of mRNA Encapsulating Lipid Nanoparticles to Sprague-Dawley Rats	6
The Metabolism of Lufotrelvir, a Prodrug Investigated for the Treatment of SARS-COV2 in Humans Following Intravenous Administration	6
Candesartan Has No Clinically Meaningful Effect on the Plasma Concentrations of Cytochrome P450 2C8 Substrate Repaglinide in Humans	6
Development of an OATP1-humanized transchromosomic mouse model for prediction of hepatic drug uptake in humans	6
Editorial Board	6
Amino Acid Solute Carrier Transporters in Inflammation and Autoimmunity	6
A Physiologically-Based Pharmacokinetic Model for Cannabidiol in Healthy Adults, Hepatically-Impaired Adults, and Children	6
Loss of Palmitoylation Impacts the Interaction between the Organic Anion Transporting Polypeptide (OATP) 1B1 and OATP1B3	6
6-Formylindolo[3,2-b]carbazole Protects Against Angiotensin II-Induced Cellular Hypertrophy through the Induction of Cytochrome P450 1A1 and Its Associated 19(S)-HETE Metabolite In Vitro	6
Absorption, Metabolism, and Excretion of Taselisib (GDC-0032), a Potent β-Sparing PI3K Inhibitor in Rats, Dogs, and Humans	6
Microbial Metabolites as Ligands to Xenobiotic Receptors: Chemical Mimicry as Potential Drugs of the Future	6
Applicability domain-expansion studies for machine learning models reveal new inhibitors of CYP2B6	5
A semimechanistic PK/PD model–informed Taxus tablets’ development: Accelerating early clinical translation of a taxane-based antitumor agent	5
Inhibition of Cytochrome P450 2J2-Mediated Metabolism of Rivaroxaban and Arachidonic Acid by Ibrutinib and Osimertinib	5
Editorial Board	5